Hypertension and cardiometabolic risk factors. by Neves, Mf et al.
Hindawi Publishing Corporation
International Journal of Hypertension
Volume 2013, Article ID 634798, 2 pages
http://dx.doi.org/10.1155/2013/634798
Editorial
Hypertension and Cardiometabolic Risk Factors
Mario Fritsch Neves,1 Agostino Virdis,2
Antonio Felipe Sanjuliani,3 and Eduardo Vera Tibiriçá4
1 Department of Clinical Medicine, State University of Rio de Janeiro, 20551030 Rio de Janeiro, RJ, Brazil
2 Department of Clinical and Experimental Medicine, University of Pisa, 56100, Italy
3 Department of Internal Medicine, State University of Rio de Janeiro, 20551030 Rio de Janeiro, RJ, Brazil
4 Laboratory of Cardiovascular Investigation, Oswaldo Cruz Institute, 21045900 Rio de Janeiro, RJ, Brazil
Correspondence should be addressed to Mario Fritsch Neves; mariofneves@gmail.com
Received 10 June 2013; Accepted 10 June 2013
Copyright © 2013 Mario Fritsch Neves et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Despite the availability of nonpharmacological approaches
and pharmacological therapies for hypertension, blood pres-
sure control rates are disappointing all over the world [1].
Among several considerations, hypertension is usually asso-
ciated with metabolic disorders, especially obesity, diabetes,
and dyslipidemia, whichmay contribute to a greater difficulty
of lowering blood pressure. In fact, the significant association
between systemic hypertension and other cardiometabolic
risk factors is well recognized, such as an elevated body mass
index, waist circumference, fasting glucose, triglycerides, and
a reduced HDL cholesterol, even not reaching criteria for
diagnosis of metabolic syndrome. Individually, each one of
these metabolic disorders is associated with adverse cardio-
vascular outcomes.
This special issue presents some papers related to these
cardiometabolic risk factors and their involvement mainly in
prognosis and treatment of hypertensive patients. Firstly, a
very low diastolic blood pressure, with a threshold value of
70mmHg, was associated with increased all-cause mortality.
It has been discussed that blood pressure level is the most
important factor in cardiovascular risk evaluation even in
hypertensive subjects with important metabolic disorders.
The linear relationship between blood pressure and cardi-
ovascularmortality starting from 115/75mmHg iswell known
[2]. Nevertheless, cardiovascular events have also been ob-
served after insistent lowering of blood pressure, at least in
patients with coronary artery disease [3].
Sleep disorders have been increasingly studied in recent
years. Obstructive sleep apnea is related to cardiovascular
disease and metabolic dysfunction, but sleep duration is a
parameter not commonly considered in this association. In-
deed, short sleep duration has been previously associated
with an increased likelihood for hypertension [4]. In a pa-
per of this collection, interactions of deficient sleep with race/
ethnicity were noted even after adjusting to metabolic factors
such as bodymass index and diabetes.This was an interesting
finding considering that insulin resistance exacerbated by
renin angiotensin system (RAS) activation might be a mech-
anism involved in the link between sleep disorders and met-
abolic syndrome. The causal relationship of RAS and oxida-
tive stress with vascular inflammation was documented in
this special issue in a study with an experimental model of
metabolic syndrome. In this protocol, a RAS inhibitor and
an antioxidant agent were able to attenuate metabolic factors
and systolic blood pressure in spontaneously hypertensive
rats submitted to fructose administration.
The interaction between hypertension and diabetes seems
to be the principal concern to the cardiovascular system.The
mechanisms that may increase cardiovascular risk in diabet-
ic hypertensive patients are not completely understood. Oxi-
dative stress and low-grade inflammation resulting in endo-
thelial dysfunction as the first process of atherosclerosis were
reviewed in this special issue. These factors may be also rele-
vant in patients with longer duration of type 1 diabetes.
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In another paper, a cross-sectional study carried out in 20
Brazilian cities demonstrated that less than one quarter of
treated type 1 diabetic patients achieved the target values for
systolic and diastolic blood pressure. These data indicate that
a more aggressive approach of this population is extremely
necessary also in developing countries.
Nutritional factors involved in the treatment of hyperten-
sive subjects are also discussed in this special issue. Many
dietary components, especially sodium, potassium, calcium,
and magnesium, are reviewed based on the available evi-
dence. Restriction of daily sodium intake is recommended
in several guidelines about hypertension. However, low salt
intake has resulted in cardiovascular mortality in some par-
ticular groups of patients including diabetic subjects [5]. Po-
tassium, calcium, and magnesium supplementations are not
indicated as a usual practice for hypertensive subjects, but
natural source of these micronutrients is the mainstay of
the Dietary Approaches to Stop Hypertension (DASH) plan.
Also, as a nonpharmacological approach, two original papers
in this collection demonstrated the beneficial effects of dark
chocolate consumption on endothelial function in specific
populations: stage 1 hypertensive subjects with excess body
weight and younger hypertensive individuals with low car-
diovascular riskwho already present endothelial dysfunction.
It has been reported that these favorable outcomes are asso-
ciated with reasonably high amount of polyphenol in dark
chocolate.
Lastly, in a study that enrolled patients with uncon-
trolled hypertension and criteria for metabolic syndrome,
moxonidine therapy resulted in blood pressure reduction and
improvement of blood pressure control rates, especially in
younger individuals. The pharmacological treatment of hy-
pertension in the context of metabolic syndrome presents
many challenges in the daily clinical practice due to several
mechanisms involved in this medical condition including
the sympathetic nervous system (SNS) hyperactivation.Thus,
moxonidine, a selective agonist at the imidazoline receptor
subtype 1 which determines a decrease in SNS activity, may
be beneficial in this circumstance.
Undoubtedly, hypertension is very commonly associated
with other metabolic chronic conditions. In fact, more than
80% of hypertensive patients present one or more concomi-
tantmetabolic risk factors.This clinical condition has a grow-
ing global prevalence, clearly related to the modern lifestyles
characterized by lack of physical activity resulting in over-
weight or obesity. Hopefully, we believe that this special issue
can help to better understand the interaction between raised
blood pressure levels and cardiometabolic factors, pointing
out the involvement of insulin resistance and RAS/SNS acti-
vation as linking factors and also discussing some therapeutic
options for this population.
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